Whether the spouses of those affected are more likely to become depressed after such events.
Blueprint to pull Gavreto in certain markets, shelve EGFR programs as it focuses on Ayvakit launch
As Blueprint Medicines braces itself for a future without a major Roche collaboration, the Massachusetts biotech is pulling its RET inhibitor from certain markets and